Immunotherapy + Chemotherapy for Gastrointestinal Cancer

(EDGE-Gastric Trial)

Not currently recruiting at 98 trial locations

Overseen By Medical Director

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Arcus Biosciences, Inc.

Must not be taking: Immune checkpoint inhibitors

Disqualifiers: Brain metastases, HER-2 positive, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 12-24 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety and effectiveness of combining immunotherapy and chemotherapy for individuals with advanced stomach, gastroesophageal junction, or esophageal cancer. It explores various treatment combinations, including the immunotherapy drugs domvanalimab and zimberelimab, with or without a chemotherapy mix called FOLFOX. The trial includes several groups to evaluate how these treatments perform for different patients, depending on their prior treatment history. This trial may suit those with locally advanced or metastatic stomach or esophageal cancer who have not responded to other treatments. As a Phase 2 trial, it focuses on measuring the treatment's effectiveness in an initial, smaller group, offering early access to potentially effective therapies.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the combination of domvanalimab and zimberelimab, sometimes used with chemotherapy like FOLFOX (a mix of drugs including oxaliplatin, leucovorin, and fluorouracil), is generally well-tolerated by patients. Studies have found no unexpected safety issues when these drugs are used together. For instance, one study found that this combination helped patients with advanced stomach cancer live longer and had manageable side effects.

Another study on zimberelimab with FOLFOX chemotherapy also found no new safety concerns, aligning with existing knowledge about these drugs' safety. FOLFOX is a standard chemotherapy treatment, and its side effects are well-known.

Research has also shown that the combination of quemliclustat and zimberelimab, even when used with chemotherapy, does not cause any new safety problems. It has a manageable safety profile, meaning the side effects are known and can be handled.

Overall, these treatments have shown promising safety results in previous studies. However, discussing any concerns with a healthcare provider before joining a clinical trial is always important. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments because they combine immunotherapy with chemotherapy to tackle gastrointestinal cancer from multiple angles. Unlike standard chemotherapy options like FOLFOX, which attack cancer cells directly, domvanalimab and zimberelimab are designed to boost the immune system's ability to recognize and destroy cancer cells. Domvanalimab is a novel anti-TIGIT antibody that may enhance the effectiveness of zimberelimab, an anti-PD-1 antibody, by preventing immune checkpoints from turning off the body's defense system. This dual approach could potentially improve outcomes for patients, offering a fresh hope for those who have tried other treatments without success.

What evidence suggests that this trial's treatments could be effective for gastrointestinal cancer?

Research has shown that combining the drugs domvanalimab and zimberelimab with chemotherapy, such as FOLFOX, yields promising results for treating advanced stomach and esophagus cancers. In this trial, some participants will receive domvanalimab and zimberelimab with FOLFOX chemotherapy. One study found that patients lived for a median of 26.7 months with this treatment. Additionally, 59% of patients responded well, indicating its effectiveness. Another study reported that this treatment led to lasting responses and long-term survival with manageable side effects. These findings suggest that this combination could be a promising option for those with advanced gastrointestinal cancers. ^{1 2 3 6 7}

Who Is on the Research Team?

Medical Director

Principal Investigator

Arcus Biosciences, Inc.

Are You a Good Fit for This Trial?

Adults with advanced cancers of the upper gastrointestinal tract, specifically gastric, GEJ, and esophageal adenocarcinoma that can't be surgically removed or has spread. They should be relatively active (ECOG score 0-1), have a life expectancy of at least 3 months, measurable cancer lesions, good organ function, and provide a tumor sample for testing.

Inclusion Criteria

I have advanced stomach or esophagus cancer and am expected to live at least 3 more months.

At least one measurable target lesion per RECIST v1.1

I can provide a sample of my cancer for testing.

Exclusion Criteria

Participants with underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational products hazardous

I am in Cohort A and my tumor is HER-2 positive.

I stopped previous immune therapy due to side effects; I've had anti-TIGIT treatment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive treatment combinations with and without chemotherapy, including FOLFOX and immunotherapy agents like domvanalimab and zimberelimab

12-24 weeks

Bi-weekly visits for chemotherapy, monthly visits for immunotherapy

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Domvanalimab
• Fluorouracil
• Leucovorin
• Oxaliplatin
• Zimberelimab

Trial Overview The study is testing combinations of new drugs Quemliclustat, Zimberelimab, Domvanalimab with/without standard chemotherapy FOLFOX (Fluorouracil + Leucovorin + Oxaliplatin) in three different groups to see which works best for treating these cancers.

How Is the Trial Designed?

Group I: Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants Experimental Treatment 2 Interventions

Domvanalimab and zimberelimab Q3W administered by IV infusion

Group II: B2: Second Line or greater Checkpoint Inhibitor Naïve Participants Experimental Treatment 2 Interventions

Quemliclustat Q2W and zimberelimab Q4W administered by IV infusion

Group III: B1: Second Line or greater Checkpoint Inhibitor Naïve Participants Experimental Treatment 2 Interventions

Domvanalimab and zimberelimab administered once every three weeks (Q3W) by IV infusion

Group IV: A4 First Line - Treatment Naïve Participants Experimental Treatment 4 Interventions

Zimberelimab administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W

Group V: A3 First Line - Treatment Naïve Participants Experimental Treatment 5 Interventions

Non-randomized A3 safety run-in cohort: Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 60 minutes in addition to FOLFOX chemotherapy via IV infusion Q2W. After completion of A3 safety run-in cohort, participants are randomized to the A3 arm. Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W

Group VI: A2: First Line - Treatment Naïve Participants Experimental Treatment 4 Interventions

Zimberelimab Q4W in addition to chemotherapy with FOLFOX administered by IV infusion Q2W

Group VII: A1: First Line - Treatment Naïve Participants Experimental Treatment 5 Interventions

Domvanalimab and zimberelimab once every 4 weeks (Q4W) in addition to FOLFOX chemotherapy by intravenous (IV) infusion once every 2 weeks (Q2W)

Who Is Running the Clinical Trial?

Arcus Biosciences, Inc.

Lead Sponsor

Trials

44

Recruited

7,500+

Gilead Sciences

Industry Sponsor

Trials

1,150

Recruited

878,000+

Daniel O'Day

Gilead Sciences

Chief Executive Officer since 2019

MBA from Columbia University

Dietmar Berger

Gilead Sciences

Chief Medical Officer

MD and PhD from Albert-Ludwigs University School of Medicine

Published Research Related to This Trial

In a phase II study involving 46 patients with advanced colorectal cancer resistant to previous treatments, the FOLFOX2 regimen (oxaliplatin, leucovorin, and 5-FU) achieved a high overall response rate of 46%, including one complete response and 20 partial responses.

The treatment was associated with manageable toxicities, primarily neutropenia (39%) and peripheral neuropathy (9%), indicating that while the regimen is effective, careful monitoring for these side effects is necessary.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. de Gramont, A., Vignoud, J., Tournigand, C., et al.[2019]

In a study of 11 patients with advanced or metastatic colorectal cancer, the FOLFOX4 regimen showed a 0% response rate, while mFOLFOX6 had a 71% response rate as a first-line therapy, indicating that mFOLFOX6 is more effective.

Patients who responded to FOLFOX4/mFOLFOX6 or FOLFIRI had significantly longer survival times (7 to 27 months) compared to those who did not respond (4 to 8 months), suggesting that these treatments can be effective for improving outcomes in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. Ohtani, H., Arimoto, Y., Nishio, K., et al.[2016]

New agents like irinotecan (CPT-11) and oxaliplatin have shown promising efficacy in treating colorectal carcinoma (CRC), especially for patients resistant to standard therapies like 5-fluorouracil (5-FU) and leucovorin.

Combination therapies involving 5-FU with newer agents such as trimetrexate, capecitabine, and S-1 are showing encouraging response rates, suggesting potential changes in the standard treatment protocols for advanced CRC in the near future.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New drugs in the treatment of colorectal carcinoma. Punt, CJ.[2019]

In a study of 66 patients with chemotherapy-refractory metastatic colorectal cancer, the combination of cetuximab with bevacizumab and mFOLFOX6 showed manageable safety, but significant toxicity led to a high discontinuation rate, with 56% of patients stopping treatment before disease progression.

Despite not causing excessive life-threatening toxicity, the addition of cetuximab resulted in a notable number of patients experiencing severe side effects, prompting the conclusion that this combination therapy should not be used together for treating metastatic colorectal cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Ocean, AJ., Polite, B., Christos, P., et al.[2021]

In a study of 570 patients with stage III colorectal cancer, three different administration types of 5-fluorouracil (5-FU) in FOLFOX treatment showed similar disease-free survival (DFS) and overall survival (OS) rates, indicating comparable efficacy.

While all treatment regimens were manageable in terms of toxicity, the modified FOLFOX-6 group experienced more grade 1-2 adverse events like thrombocytopenia and neuropathy, suggesting that while efficacy is similar, side effects may vary among the different regimens.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. Akdeniz, N., Kaplan, MA., Uncu, D., et al.[2021]

The combination of oral doxifluridine (d-FUR) and l-leucovorin showed some efficacy in treating gastric cancer, with a 15% objective response rate in a study of 50 patients, primarily those previously treated with 5-FU.

While the treatment was well tolerated with moderate toxicity, including 14% experiencing severe diarrhea, the results for pancreatic cancer were less promising, with only a 4% response rate, consistent with existing literature on fluoropyrimidines.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Di Bartolomeo, M., Bajetta, E., Somma, L., et al.[2018]

In a study involving 508 patients with untreated metastatic colorectal cancer, the combination of FOLFOXIRI and bevacizumab significantly improved progression-free survival (12.1 months) compared to FOLFIRI and bevacizumab (9.7 months), indicating enhanced treatment efficacy.

While FOLFOXIRI plus bevacizumab showed better outcomes, it also resulted in higher rates of severe side effects, such as neurotoxicity and diarrhea, highlighting the need to balance treatment benefits with potential risks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. Loupakis, F., Cremolini, C., Masi, G., et al.[2022]

In a phase III study involving 220 previously untreated patients with metastatic colorectal cancer, both treatment sequences (FOLFIRI followed by FOLFOX6 and vice versa) resulted in similar median survival rates of approximately 21.5 months and 20.6 months, indicating comparable efficacy.

The study revealed distinct toxicity profiles for each treatment sequence, with FOLFIRI causing more mucositis and nausea/vomiting, while FOLFOX6 was associated with higher rates of neutropenia and neurosensory toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Tournigand, C., André, T., Achille, E., et al.[2023]

In a phase III study of 220 previously untreated patients with metastatic colorectal cancer, both treatment sequences (FOLFIRI followed by FOLFOX6 and vice versa) resulted in similar median survival rates of approximately 21.5 months and 20.6 months, indicating comparable efficacy.

The study revealed distinct toxicity profiles for the two treatment sequences, with FOLFIRI causing more mucositis and nausea/vomiting, while FOLFOX6 was associated with higher rates of neutropenia and neurosensory toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Tournigand, C., André, T., Achille, E., et al.[2023]

S-1, an oral chemotherapy drug combining tegafur with modulators, has shown advantages over standard 5-FU-based treatments for gastric cancer in large Phase III studies, making it a recommended option in treatment guidelines.

S-1, either alone or in combination with cisplatin, is non-inferior to traditional 5-FU regimens while offering greater convenience and reduced toxicity, highlighting its potential for higher efficacy in treating gastrointestinal cancers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

S-1 for the treatment of gastrointestinal cancer. Satoh, T., Sakata, Y.[2022]

The FOLFOX regimen, which combines Leucovorin and fluorouracil with oxaliplatin, is a standard first-line treatment for metastatic colorectal cancer, but it has significant side effects including neutropenia and sensory neuropathy.

Immediate hypersensitivity reactions, such as anaphylaxis, can occur in up to 0.6% of patients receiving FOLFOX, highlighting the importance of monitoring for adverse effects during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[FOLFOX]. Mishima, H., Ikenaga, M., Tsujinaka, T., et al.[2013]

The combination of oxaliplatin and irinotecan with continuous infusion of 5FU has significantly improved treatment outcomes for metastatic colorectal cancer, leading to better response rates and overall survival compared to earlier treatments.

The ongoing trials, such as Optimox2, are exploring strategies to reduce treatment cycles and toxicity while maintaining efficacy, alongside promising new targeted therapies against EGFR and VEGF, which could further enhance treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer]. Tournigand, C., de Gramont, A.[2018]

Citations

1. investors.arcusbio.com investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2025/Anti-TIGIT-Domvanalimab-Plus-Anti-PD-1-Zimberelimab-and-Chemotherapy-Showed-26-7-Months-of-Median-Overall-Survival-as-First-Line-Treatment-of-Unresectable-or-Advanced-Gastroesophageal-Adenocarcinomas-in-the-Phase-2-EDGE-Gastric-Study/default.aspx

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab ... Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of ...

2. onclive.com onclive.com/view/domvanalimab-plus-zimberelimab-and-chemo-set-for-phase-3-study-after-showing-efficacy-in-untreated-upper-gi-cancers

Domvanalimab Plus Zimberelimab and Chemo Set for ... STAR-221 will evaluate domvanalimab plus zimberelimab and chemotherapy for the first-line treatment of patients with gastric, GEJ, or esophageal adenocarcinoma.

3. oncodaily.com oncodaily.com/oncolibrary/immune-oncology/edge-gastric-study

EDGE Gastric Study at ESMO 2025: Domvanalimab ... At a 26-month follow-up, the combination demonstrated durable efficacy, achieving a median overall survival (OS) of 26.7 months and median ...

4. nature.com nature.com/articles/s41591-025-04022-w

Domvanalimab and zimberelimab in advanced gastric ... In preclinical studies, chemotherapy followed by dual checkpoint blockade with domvanalimab and zimberelimab potentiated a robust and durable ...

5. clinicaltrials.gov clinicaltrials.gov/study/NCT04791839

Study Details | NCT04791839 | Safety and Efficacy of ... Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12219336/

Dual TIGIT and PD-1 blockade with domvanalimab plus ... A caveat to the safety data of the LIVERTI trial is that patients with high grade toxicities to prior immunotherapies were excluded, and the ...

7. ascopubs.org ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4236

IMMUNORARE5: A national platform of 5 academic phase ... IMMUNORARE 5 (NCT06790706) is a platform of 5 single arm phase II trials testing the safety and the efficacy of DOMVANALIMAB (anti-TIGIT) and ZIMBERELIMAB ( ...